Skip to search formSkip to main contentSkip to account menu

OXT-328

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Organophosphorus CompoundsSulindac
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Phosphosulindac (OXT‐328) Selectively Targets Breast Cancer Stem Cells In Vitro and in Human Breast Cancer Xenografts
Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small… 
2012
2012
The metabolism and pharmacokinetics of phospho‐sulindac (OXT‐328) and the effect of difluoromethylornithine
BACKGROUND AND PURPOSE Phospho‐sulindac (PS; OXT‐328) prevents colon cancer in mice, especially when combined with… 
2012
2012
Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer
Phospho-sulindac (P-S, OXT-328), a novel sulindac derivative, has shown superior anticancer efficacy and safety compared to… 
2012
2012
cacy of topical P-S hydrogel in the treatment of non-melanoma skin cancer in preclinical models. P-S is a potent inhibitor of A431 epidermoid carcinoma in vitro and achieves this effect by inhibiting…
Phospho-sulindac (P-S, OXT-328), a novel sulindac derivative, has shown superior anticancer efficacy and safety compared to… 
Highly Cited
2011
Highly Cited
2011
The novel phospho‐non‐steroidal anti‐inflammatory drugs, OXT‐328, MDC‐22 and MDC‐917, inhibit adjuvant‐induced arthritis in rats
BACKGROUND AND PURPOSE The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) in the treatment of rheumatoid arthritis (RA) is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)